<DOC>
	<DOCNO>NCT01166763</DOCNO>
	<brief_summary>The overall goal project determine high dose vitamin D3 give premenopausal woman high risk development breast cancer , initially insufficient level 25-hydroxy vitamin D ( &lt; 30 ng/ml ) , raise 25 ( OH ) D level 50 ng/ml . If , certain risk biomarkers development breast cancer reliably favorably modulate ?</brief_summary>
	<brief_title>Modulation Breast Cancer Risk Biomarkers High Dose Vitamin D</brief_title>
	<detailed_description>Protocol Objectives : To determine high dose vitamin D3 give premenopausal woman initially insufficient level 25-hydroxy vitamin D ( &lt; 30 ng/ml ) raise 25 ( OH ) D level 50 ng/ml level consider require breast health . If , certain risk biomarkers development breast cancer reliably favorably modulate ? The primary endpoint decrease mammographic breast density ( percent area consider increased density ) . Change proliferation ( decrease assess Ki-67 ) also examine . Modulate expression gene important breast cancer risk reflective vitamin D 's mechanism action study use quantitative real time polymerase chain reaction ( qRT-PCR ) . Study Design : The study single-arm open label clinical trial . Women high risk development breast cancer basis family personal history undergo random periareolar fine needle aspiration ( RPFNA ) acquire breast cell assessment gene expression qRT-PCR . Women mammographic density &gt; 10 % eligible enrollment . All subject receive high dose vitamin D3 ( 3 capsule 10,000 IU vitamin D3 every week 6-8 month ) . At time , repeat RPFNA mammogram perform . Measurement serum level 25 ( OH ) D perform baseline , 3 month , 6 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>Subjects must premenopausal woman age 55 young , actively menstruate 4 period per year . Subjects may use barrier contraceptive , intrauterine device , Nuvaring , similar nonoral contraceptive ; oral contraceptive . Subjects must increase risk breast cancer basis least one follow criterion : fiveyear Gail risk 3X average risk age group ; first degree relative breast cancer age 60 multiple second degree relative breast cancer ; prior biopsy exhibit atypical hyperplasia ( AH ) , LCIS , DCIS , RPFNA evidence hyperplasia atypia within last three year ; Chest neck radiation age 30 ; Breast density equal exceed 50 percent . If previously chemoprevention agent prevention trial , subject must complete study participation least 6 month prior baseline biomarker assessment . If subject history AH , LCIS , ERpositive DCIS diagnostic biopsy , must counsel appropriate standard prevention therapy tamoxifen either eligible interested standard prevention therapy . Women DCIS must appropriate local therapy ( lumpectomy plus radiation mastectomy ) . Subject must mammogram perform University Kansas Breast Imaging Center estimate visual breast density great 10 percent . Subject must within six month prior enter study , RPFNA follicular portion ( day 110 ) menstrual cycle material cytomorphology , Ki67 qRTPCR ; addition serum obtain bank . Subjects must 25 ( OH ) D level &lt; 30 ng/ml measure within 8 week start intervention . Subjects may identify low vitamin D level participation HSC 11313 , Osteopenia/Osteoporosis Premenopausal Women High Risk Development Breast Cancer , low level must confirm within 8 week prior start study agent Subject must willing continue hormonal milieu present baseline throughout trial . Subjects must willing undergo measurement height , weight , BMI initiation intervention . Subjects must participate HSC 11313 , DEXA scan bone density body fat analysis GE Lunar Prodigy Advance research unit Breast Cancer Survivorship Center . Subjects must willing sign inform consent entire study separate consent repeat RPFNA . Women metastatic malignancy kind . Women prior invasive breast cancer If subject DCIS , least two month must elapse surgery and/or radiation therapy involve breast . Only contralateral ( uninvolved breast ) study FNA . The subject may radiation therapy contralateral breast study . Women pregnant nursing . Women take SERM , aromatase inhibitor participate chemoprevention investigational drug study within six month prior baseline FNA . Women use fertility drug within six month prior baseline aspiration . Women history sarcoidosis , hypercalcemia , hyperparathyroidism , renal stone . Women receive treatment rheumatoid arthritis connective tissue disease . Women elevate blood calcium level baseline ; define elevation institutional normal range .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>breast atypia</keyword>
	<keyword>high risk breast cancer</keyword>
	<keyword>random periareolar fine needle aspiration</keyword>
	<keyword>RPFNA</keyword>
	<keyword>breast epithelial hyperplasia</keyword>
	<keyword>ki-67</keyword>
	<keyword>chemoprevention</keyword>
	<keyword>vitamin D3</keyword>
	<keyword>Additional relevant MeSH term :</keyword>
	<keyword>Molecular Mechanisms Pharmacological Action</keyword>
	<keyword>Physiological Effects Drugs</keyword>
	<keyword>Breast Neoplasms</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Hyperplasia</keyword>
	<keyword>high risk development breast cancer</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Neoplasms Site</keyword>
	<keyword>Pathologic Processes</keyword>
	<keyword>Antirheumatic Agents</keyword>
	<keyword>Breast Diseases</keyword>
</DOC>